Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to the β4 integrin subunit
- 25 May 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 32 (6), 637-641
- https://doi.org/10.1111/j.1365-2230.2007.02463.x
Abstract
Background. Mucous membrane pemphigoid (MMP) is a mucocutaneous vesiculobullous autoimmune disease characterized by autoantibodies to components of the basement membrane zone (BMZ). Recently, it has been reported that patients with MMP who have autoantibodies to laminin 5, known as anti‐epiligrin cicatricial pemphigoid (AECP) have a high incidence of malignancy. Objective. The purpose of this study was to determine the association between malignancy and MMP in patients with antibodies to β4 integrin. Methods. The incidence of cancer was studied in 79 patients with MMP and/or ocular cicatricial pemphigoid (OCP) who had antibodies to human β4 integrin subunit. In each patient, the diagnosis was made by histology and confirmed by immunopathology of affected tissues. It was compared to the expected incidence, for age‐ and gender‐matched individuals, in the National Cancer Institute's Surveillance, Epidemiology and End Results (NCISEER) database. Results. Of 79 patients, 3 had cancer. The relative risk (RR) for cancer in patients with MMP and/or OCP, with autoantibodies to human β4 integrin subunit was 0.29 (95% CI 0.62–8.77). The expected number in the NCISEER database was 10.37. This difference was statistically significant (P < 0.01). Conclusion. This incidence of cancer in MMP/OCP patients, with antibodies to human β4 integrin subunit is considerably lower than expected. Preliminary observations in this and other studies suggest that serological subsets of MMP, based on antigen reactivity, have a different clinical course, prognosis and associations with cancer.Keywords
This publication has 19 references indexed in Scilit:
- Screening of Blood Donations for HIV-1 and HCV RNA by Transcription-Mediated Amplification Assay: One Year ExperienceTransfusion Medicine and Hemotherapy, 2004
- Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human α6 integrinClinical and Experimental Immunology, 2002
- Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230British Journal of Dermatology, 2001
- Anti-epiligrin cicatricial pemphigoid and relative risk for cancerThe Lancet, 2001
- Cicatricial pemphigoidJournal of the American Academy of Dermatology, 2000
- Influence of intravenous immunoglobulin therapy on serum levels of anti- 4 antibodies in ocular cicatricial pemphigoid: A correlation with disease activityCurrent Eye Research, 2000
- Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5British Journal of Dermatology, 1999
- Oral pemphigoid: Subset of cicatricial pemphigoid?Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 1998
- Anti-epiligrin (laminin 5) cicatricial pemphigoid and lung carcinoma: coincidence or association?British Journal of Dermatology, 1997
- Ocular cicatricial pemphigoid antigen: Partial sequence and biochemical characterizationProceedings of the National Academy of Sciences of the United States of America, 1996